Ophthalmic Sciences Announces Appointment of Ariel Weinstein as CEO

Tel Aviv, September 1, 2020  –  Ophthalmic Sciences, an emerging company focused on developing the first ever contactless AI-based intraocular pressure (IOP) measuring device, is pleased to announce the strengthening of its management team by electing Mr. Ariel Weinstein as its Chief Executive Officer.

A medtech veteran, Mr. Weinstein, 45, CEO of OCON Healthcare for the past nine years, brings with him exceptional concept-to-market experience, having brought a drug-device class III products through the idea stage all the way to the market, with well over 100K product users as well as a strategic cooperation with a major global pharmaceuticals company. Prior to OCON, he served as General Manager of Nitiloop Ltd, a cardiology focused company, at Intramed Systems, an orthopedic company focused on specialized intramedullary nails, at Disc-O-Tech, an orthopedic company (sold in US$240M to Kyphon) in clinical and development roles and as manager of a cardiovascular facility at a major US hospital. Mr. Weinstein holds a BSc in Emergency Medicine from Ben-Gurion University and a Masters in Management from NYU and is a certified paramedic.

Commenting on his appointment, Mr. Weinstein said: “I am excited about leading Ophthalmic Sciences as the new CEO at this stage of the Company, as the concept has matured. I look forward to working with the team to promote our R&D activities , secure key regulatory approvals and form strategic collaborations. I believe the Company holds the key to a superior breakthrough in a huge market without a significant unmet need.”

“Mr. Weinstein brings to the table a wealth of experience, know-how and connection and we are confident he will add significant value to this highly promising and innovative company” said Talor Sax, Company Chairman and CEO of eHealth Ventures.

Intraocular pressure measurement is conducted in developed countries on a yearly basis to detect and avoid glaucoma – a major eye disease that can lead to permanent blindness if left untreated. Current measuring is done by uncomfortable devices that require physical contact with the surface of the eye and often produce imprecise results. Ophthalmic Sciences is developing a first-in-kind portable device that would measure the intraocular pressure on a purely visual basis, using artificial-intelligence image processing technology without the need for pre-medication or eye contact. Considering over 75M diagnosed glaucoma patients who require continuous follow-up in addition to 200K ophthalmologists, the global year-by-year market is worth well over US$100M. Its scientific success places Ophthalmic Sciences in a unique position to meet the ever-increasing unmet demand for highly accessible, accurate and user-friendly intraocular pressure measuring.


For more information on Ophthalmic Sciences: ariel@op-sci.com

For eHealth Ventures, contact ophir@ehv.health